Clinical Trial Update: Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating a quadruple regimen of trastuzumab, pertuzumab, docetaxel, and QL1706 in patients with early or locally advanced HER2-posit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Perjeta (pertuzumab)
• QL1706
• Taxotere (docetaxel)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING